PROCEPT BioRoboticsPRCT +5.77%70 3-1 Month Momentum % is 25.39% as of Jul. 12, 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $93.13 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 849 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 90.58% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-12), PROCEPT BioRobotics's 3-1 Month Momentum % is 25.39%.
The industry rank for PROCEPT BioRobotics's 3-1 Month Momentum % or its related term are showing as below:
PRCT's 3-1 Month Momentum % is ranked better than 90.58% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: -6.91
vs PRCT: 25.39
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
PROCEPT BioRobotics 3-1 Month Momentum % Related Terms
PRCT vs ENOV, INSP, IRMD: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a 3-1 Month Momentum % of 25.39% as of Jul. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PROCEPT BioRobotics and its competitors. According to the industry distribution chart, PROCEPT BioRobotics ranks #80 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 9.4%.
Is PROCEPT BioRobotics' 3-1 Month Momentum % too high?
PROCEPT BioRobotics' current 3-1 Month Momentum % is 25.39%. Based on the distribution chart, PROCEPT BioRobotics ranks #80 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' 3-1 Month Momentum % compare to ENOV and INSP?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #80 out of 849 companies for 3-1 Month Momentum %. This places PROCEPT BioRobotics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current 3-1 Month Momentum % is 25.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $93.13, compared to a current price of $20.90 — trading 77.6% below its estimated fair value. The current 3-1 Month Momentum % is 25.39%. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current 3-1 Month Momentum % is 25.39% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $20.90 is trading 77.6% below its estimated GF Value™ of $93.13.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
3-1 Month Momentum %: 25.39%
GF Value™: $93.13 vs. price of $20.90 (77.6% below fair value)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 